FTC challenges over 100 patents in FDA’s Orange Book
The Federal Trade Commission has disputed over 100 patents in the Food and Drug Administration’s Orange Book that the agency says may stall generic competition.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10